Valeant's outgoing CEO made an insane amount of money last year

Valeant Pharmaceuticals’ outgoing CEO Michael Pearson made $143.1 million in 2015, according to Dow Jones.

It was the year the international giant was brought to its knees.

In October accusations of malfeasance from a short seller combined with government scrutiny over Valeant’s drug pricing practices to drag its stock down almost 70%.

Pearson stepped down from the company earlier this month, after it was forced to change its business model, shut down a previously undisclosed internal pharmacy called Philidor, and filed its annual report over a month late, risking defaulting on its $30 billion debt load.

On Wednesday, Pearson, the company’s former CFO and billionaire hedge fund investor and board member Bill Ackman testified before Congress, answering for hiking the prices of a number of critical drugs to exhorbitant levels.

Since then the company has also announced that longstanding board members will step down.

New CEO Joe Papa starts on Monday.

NOW WATCH: How ISIS makes over $1 billion a year

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at research.businessinsider.com.au.